首页> 外文期刊>Journal of thrombosis and haemostasis: JTH >Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient
【24h】

Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient

机译:成功的肝脏从血友病中移植富含血友病A中的血友病

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Hemophilia A is an X‐linked inherited bleeding disorder caused by deficiency of coagulation factor VIII. Factor VIII is activated as part of the intrinsic coagulation cascade. It plays a crucial role as the cofactor in the intrinsic “tenase” complex activating factor X to assist in clot formation. Absence or mutation of this coagulation factor leads to excessive bleeding. Clinical manifestations of hemophilia relate to bleeding from impaired hemostasis, sequelae from bleeding, or complications of coagulation factor infusion. Diagnostic criteria for Hemophilia A include factor VIII activity level below 40% of normal, presence of a mutated F8 gene, and the absence of von Willebrand disease ( F8 gene ‐ Genetics Home Reference ‐ NIH. https://ghr.nlm.nih.gov/gene/F8 ). Patients who have this intrinsic defect in the coagulation cascade have a characteristically prolonged PTT. It is theorized that the majority of factor VIII is synthesized mainly in the liver, by way of liver sinusoidal endothelial cells (Arruda VR. Haematologica . 2015;100(7):849–850). Extrahepatic production also occurs in the endothelial cells, kidneys, and lymphatic tissue. In 1969, Marchioro et al showed that transplantation of normal liver to hemophilia dog could normalize plasma factor VIII levels (Marchioro T L, Science . 1969;163(3863):188–190). These results were subsequently proven in humans. Liver transplantation from hemophilia A donors without factor VIII inhibitor is not commonly performed due to the perceived risk of developing hemophilia A in the recipient. There is currently limited literature aimed at elucidating this risk. We present a case of liver transplantation in a hemophilia A donor to a recipient with no history of hemophilia A with literature reviewis a case report, objective and method do not apply. Objective and method We did a case report and literature review of a liver transplant receipient fro ma hemohpila A donor. Results The receipient of the liver from hemophilia A donor did not develop hemophilia post transplant and had normal factor VIII levels. conclusion To our knowledge, this is only the second case in humans of hemophilia A patient as a donor in liver transplantation. As the indications for liver transplantation have expanded, there is a need to expand the donor list, and possibly not exclude this population as viable donor option.
机译:摘要背景血友病A是由凝血因子VIII缺乏引起的X链接遗传性出血障碍。因子VIII被激活为内在凝固级联的一部分。它在内在的“诱导”复杂的激活因子X中起着至关重要的作用,以协助凝块形成。这种凝血因子的缺失或突变导致过度出血。血友病的临床表现涉及从止血受损,出血后遗症的出血,或凝血因子输注的并发症。血友病的诊断标准包括突变的F8基因的正常情况低于40%的因子VIII活性水平,以及缺乏von willebrand疾病(F8基因 - 遗传学家庭参考 - NIH。HTTPS://GHR.NLM.nih。 gov / gene / f8)。在凝固级联中具有这种固有缺陷的患者具有特征性地延长的PTT。理论上,大多数因子VIII通过肝窦内皮细胞主要在肝脏中合成(Aruda VR。2015年; 100(7):849-850)。脱胸部产生也发生在内皮细胞,肾脏和淋巴组织中。 1969年,Marchioro等人表明,正常肝脏移植到血友病犬可以正常化血浆因子VIII水平(Marchioro T L,Science。1969; 163(3863):188-190)。随后这些结果被证明在人体中。由于在接受者中发育血友病A的风险,血友病血友病患者的血友移植不常见于没有因子VIII抑制剂的供体。目前有有限的文学旨在阐明这种风险。我们在血友病中呈现肝移植的情况,给血友病患者没有血友病历史,案例报告,目标和方法不适用。目的和方法我们对肝移植接收的案例报告和文献综述来回血清虫捐赠者。结果血友病患者的肝脏的接收因子未发生血友病后移植,并且具有正常因素VIII水平。结论到我们的知识,这只是血友病的第二种病例,患者作为肝移植中的供体。随着肝移植的适应症扩大,需要扩大捐助者清单,并且可能不会将该人口排除为可行的捐赠者选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号